ABSTRACT NUMBER: ESOC2026A562 CEREBROLYSIN AFTER ENDOVASCULAR THROMBECTOMY IN STROKE: 12-MONTH FUNCTIONAL OUTCOMES IN A PROPENSITY-MATCHED COHORT
Jacek Staszewski, Aleksander Dębiec, Katarzyna Agnieszka Gniadek Olejniczak, Piotr Piasecki · 2026
Read ABSTRACT NUMBER: ESOC2026A562 CEREBROLYSIN AFTER ENDOVASCULAR THROMBECTOMY IN STROKE: 12-MONTH FUNCTIONAL OUTCOMES IN A PROPENSITY-MATCHED COHORT by Jacek Staszewski, Aleksander Dębiec, Katarzyna Agnieszka Gniadek Olejniczak, Piotr Piasecki (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13146562.txt.
Description
Jacek Staszewski and co-authors report a 2026 conference study on a drug given after clot removal in stroke care. The drug is Cerebrolysin, and patients got it by vein for set courses after the procedure. The team asked whether adding the drug linked to better function one year later.
Fifty treated patients were matched with fifty past patients who had clot removal alone. At one year, the drug group had higher odds of living on their own and better daily task scores. Death rates were the same in both groups, at eighteen percent. The authors warn that hidden bias may remain and call for a strict trial to test the drug.
Catalog record
| CREATOR | Jacek Staszewski, Aleksander Dębiec, Katarzyna Agnieszka Gniadek Olejniczak, Piotr Piasecki |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |